The Lancet, August 2020

At the start of the pandemic, ISARIC4C was able to provide convalescent samples of PCR-positive hospitalised patients with COVID-19 to characterise the immunological properties of COVID-19. This was essential to the development of the viral vectored coronavirus vaccine developed by the Oxford COVID Vaccine Trial Group.